Idorsia In Dreamland With Insomnia Drug Approval
FDA Green Light For Daridorexant
Executive Summary
The Swiss biotech has got the thumbs up in the US for its insomnia drug which will be sold as Quviviq and is expected to be provide serious competition for Merck & Co's rival dual orexin receptor antagonist Belsomra.
You may also be interested in...
Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023
With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.
Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.